Oculis (OCS) Stock Price, News & Analysis

Company Overview

Oculis (NASDAQ: OCS) is a biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. The company aims to address significant unmet needs in ophthalmology through therapies designed for topical, noninvasive administration and other targeted delivery approaches.

Oculis’ pipeline has included OCS-01, a topical dexamethasone formulation being developed for retinal diseases such as diabetic macular edema, and licaminlimab (OCS-02), an ophthalmic anti-TNF biologic being investigated for conditions including dry eye disease. The company has also pursued OCS-05, an investigational neuroprotective therapy for disorders affecting the optic nerve and retina. Pipeline programs and development priorities may change as clinical research progresses.

Founded in Switzerland, Oculis has developed its programs for international markets and conducts research and clinical activities across multiple regions. The company became publicly listed on Nasdaq in 2023 following a business combination with European Biotech Acquisition Corp. Oculis is led by Chief Executive Officer Riad Sherif, M.D.

Key Stats

• Today's Range: $8.30 to $8.75
• 50-Day Range: $8.34 to $13.57
• 52-Week Range: $8.30 to $34.47
• Volume: 161,880 shs
• Average Volume: 295,693 shs
• Market Capitalization: $483.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.44
• Consensus Rating: Moderate Buy

Oculis Stock Analysis - MarketRank™

Oculis scored higher than 43% of companies evaluated by MarketBeat, and ranked 555th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oculis has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Oculis has a consensus price target of $39.44, representing about 373.0% upside from its current price of $8.34.

Amount of Analyst Coverage

Oculis has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Oculis are expected to decrease in the coming year, from ($2.01) to ($2.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oculis is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oculis is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oculis has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.05% of the float of Oculis has been sold short.

Short Interest Ratio / Days to Cover

Oculis has a short interest ratio ("days to cover") of 6.48.

Change versus previous month

Short interest in Oculis has recently increased by 14.09%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oculis does not currently pay a dividend.

Dividend Growth

Oculis does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.37

News Sentiment

Oculis has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Oculis this week, compared to 5 articles on an average week.

Search Interest

Only 3 people have searched for OCS on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oculis insiders have not sold or bought any company stock.

Percentage Held by Institutions

22.30% of the stock of Oculis is held by institutions.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:OCS
• CIK: 1953530
• Web: www.oculis.com
• Phone: 41-21-711-3970
• Fax: N/A
• Employees: 60
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Oculis: $39.44
• High Price Target: $55.00
• Low Price Target: $20.00
• Potential Upside/Downside: +373.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.74)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$119.44 million
• Net Margins: -6,777.18%
• Pretax Margin: -6,956.07%
• Return on Equity: -42.61%
• Return on Assets: -35.23%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 8.35
• Quick Ratio: 8.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.08 per share
• Price / Book: 2.04

Miscellaneous

• Outstanding Shares: 57,984,000
• Free Float: N/A
• Market Cap: $483.59 million
• Optionable: Not Optionable
• Beta: 0.62